The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 February 2026•

1 min read

Beam Therapeutics Secures $500 Million Non-Dilutive Financing for Risto-cel Launch

Key Facts

1Beam Therapeutics announced a $500 million strategic financing agreement with Sixth Street.

2$100 million was funded at close, with up to an additional $400 million available under the facility.

Beam Therapeutics Inc. (Nasdaq: BEAM) has announced a strategic financing agreement worth up to $500 million with investment firm Sixth Street. The arrangement provides $100 million in immediate funding at closing, with an additional $400 million available through the facility. This non-dilutive capital is structured with a seven-year term, specifically designed to support the commercial launch of Risto-cel, a treatment for sickle cell disease. By securing this funding, the company strengthens its balance sheet without diluting existing shareholder equity. The move extends Beam's cash runway during a critical phase as it prepares for the anticipated market entry of its lead therapeutic candidate.